JAK Inhibitor Scaffold for Selective JAK-STAT Pathway Blocking

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current JAK inhibitors, such as Oclacitinib and Baricitinib, have limited efficacy and scope in treating inflammatory diseases and neoplastic diseases, as they do not effectively block the JAK-STAT pathway and have narrow indications, necessitating the development of a JAK inhibitor with broader application and lower toxicity.

Innovation Solution

A novel JAK inhibitor represented by a specific chemical formula, allowing for the synthesis of a compound that can inhibit JAK kinase, potentially blocking the JAK-STAT pathway more effectively, with a broader range of therapeutic applications and reduced toxicity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current JAK inhibitors (Oclacitinib, Baricitinib) are used, then JAK kinase inhibition is achieved, but efficacy is limited and application scope is narrow

Engineering Contradiction:

ImproveefficacyVSAvoidapplication scope

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent describes a series of JAK inhibitor compounds with broad-spectrum activity against multiple JAK isoforms (JAK1, JAK2, JAK3, Tyk2). The chemical structures are designed to inhibit JAK kinase activity across different disease indications including inflammatory diseases (rheumatoid arthritis, psoriasis, IBD), neoplastic diseases (myelofibrosis, polycythemia vera), and allergic reactions, making the inhibitor universally applicable rather than indication-specific

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Reliability

If JAK inhibitors are administered to achieve therapeutic effects, then disease symptoms are relieved, but toxicity increases

Engineering Contradiction:

Improvetherapeutic effectVSAvoidtoxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent employs structure-activity relationship optimization where specific chemical groups and molecular features are modified to enhance selectivity for JAK kinase over other kinases. The compounds are designed with specific pharmacophoric elements that target JAK ATP-binding sites while minimizing off-target effects, thereby reducing toxicity while maintaining therapeutic efficacy

Inventive Principle:

Principle #3Local quality

3Reliability

If JAK inhibitors block JAK-STAT pathway, then cytokine signaling is inhibited, but selectivity is insufficient leading to limited efficacy

Engineering Contradiction:

Improvepathway blocking capabilityVSAvoidselectivity deficiency

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent utilizes IC50 values and selectivity ratios as key parameters to optimize compound performance. The chemical structures are designed and screened based on their ability to achieve nanomolar-range IC50 values for JAK inhibition while maintaining selectivity ratios greater than 10-fold over other kinases, thereby ensuring both effective pathway blocking and sufficient selectivity

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS12509463B2JAK inhibitor and preparation method therefor

Publication Date: 2025.12.30 FELICAMED BIOTECHNOLOGY CO LTD

AI summary

The present invention provides a compound represented by a general formula I and a pharmaceutically acceptable salt, stereisomer, ester, prodrug, metabolite, solvate, or deuterated compound thereof. The compound is a JAK inhibitor and can prevent and/or treat an inflammatory disease or cancer in humans and/or animals.